Prodecis will enable 360 Oncology to deliver genomics-based evidence to help clinicians make more informed decisions.
Prodecis is a clinical-grade multifactor decision support system integrating all currently available patient data to allow personalized treatment of cancer.
The predictive models based on toxicity, tumor control, quality of life and cost effectiveness, enhance the ability of 360 Oncology to provide the information needed by a clinician to recommend the optimal individualized treatment for each patient.
DNAmito, headquartered in Palo Alto, California, has a significant presence in Europe through its ptTheragnostic R and D office in the Netherlands. DNAmito solutions provide genomics-based personalized analysis for radio-sensitivity to optimize radiation treatment for cancer.
Varian Medical Systems is a manufacturer of medical devices and software for treating and managing cancer. The company employs approximately 6,600 people around the world.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories